STOCK TITAN

Revvity Inc. - PKI STOCK NEWS

Welcome to our dedicated news page for Revvity (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on Revvity.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revvity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revvity's position in the market.

Rhea-AI Summary
Revvity (RVTY) Board announces a regular quarterly dividend of $0.07 per share of common stock payable on August 9, 2024, to shareholders of record as of July 19, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) is set to present at the BofA Securities 2024 Health Care Conference on May 14, 2024. Senior Vice President and CFO Max Krakowiak will discuss the Company's strategic priorities. The presentation will be live-streamed on Revvity's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) unveils the Auto-Pure 2400 liquid handler for use with the T-SPOT.TB test, revolutionizing tuberculosis testing. The new system substantially reduces hands-on time, boosting lab productivity. Labs, clinicians, and patients benefit from the efficient workflow and clinical accuracy of the combined solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals SynergyTM, a software solution enhancing collaboration between pharmaceutical and biotechnology sponsors and their contract partners. Signals Synergy aims to streamline processes, improve data stewardship, and reduce errors and delays in project management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (RVTY) will release its Q1 2024 financial results on April 29, 2024, followed by a conference call hosted by the CEO and CFO. Investors can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) has been granted a preliminary injunction by the Massachusetts Superior Court against Cloud Software Group (CSG) for breaching contractual obligations. The injunction mandates CSG to cease all activities in Revvity's exclusive markets and continue maintenance services for Spotfire® software. Revvity emphasizes its dedication to customer service and satisfaction, ensuring uninterrupted service for its customers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
Rhea-AI Summary
Revvity, Inc. (RVTY) files a complaint against Cloud Software Group for breaching strategic partnership obligations related to Spotfire® software. Revvity reaffirms 2024 revenue guidance amidst legal dispute.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ChemDraw, a cutting-edge chemistry suite enhancing research productivity and collaboration in chemical, pharmaceutical, and biotechnology industries. The software aims to streamline communication of complex chemical concepts, promote interdisciplinary cooperation, and boost research efficiency. Signals ChemDraw offers intuitive design, advanced features, and cloud-native architecture, catering to the evolving needs of the scientific community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) will present at several investor conferences in February and March 2024, providing updates on the company's strategic priorities. Key executives like Max Krakowiak and Prahlad Singh will discuss the financial and operational aspects at these events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.76%
Tags
conferences
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) introduces Signals ClinicalTM, a centralized data science platform integrated with Spotfire for efficient clinical study data management, enabling quick clinical decisions and therapeutic advancements. The platform emphasizes cross-functional collaboration, customization, and scalability to enhance clinical research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.37%
Tags
Revvity Inc.

NYSE:PKI

PKI Rankings

PKI Stock Data

14.46B
116.15M
0.27%
86.26%
2.79%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
Boston

About PKI

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.